{
	"l1liutk6Text": "REVIDA<span class=\"_ _e\"> </span>At-W<span class=\"_ _1\"></span>oRC<span class=\"_\"> </span><span class=\"ff6 fc1\">RELIEVE</span>",
	"l1liutk7Text": "Data fr<span class=\"_ _1\"></span>om routine clinical pr<span class=\"_ _1\"></span>actice show clinically <br>meaningful impr<span class=\"_ _1\"></span>ovements<span class=\"fse wsd v6\">†</span><span class=\"v0\"> in functioning<span class=\"fse wsd v6\">‡</span> <br>in patients with MDD tr<span class=\"_ _1\"></span>eated with Brintellix<span class=\"fse v6\">®§1</span></span>",
	"l1liutk8Text": "Change from baseline in SDS scor<span class=\"_ _1\"></span>es at week 12 and week 24<span class=\"fs9 v3\">§</span>",
	"l1liutk9Text": "LS mean change from baseline ",
	"l1liutkaText": "-2.0",
	"l1liutkbText": "-4.0",
	"l1liutkcText": "-3.0",
	"l1liutkdText": "-6.0",
	"l1liutkeText": "-5.0",
	"l1liutkfText": "-8.0",
	"l1liutkgText": "-9.0",
	"l1liutkhText": "-7.0",
	"l1liutkiText": "-10.0",
	"l1liutkjText": "0.0",
	"l1liutkkText": "-1.0",
	"l1liutklText": "-2.2",
	"l1liutkmText": "-2.9",
	"l1liutknText": "-2.4",
	"l1liutkoText": "-3.0",
	"l1liutkpText": "-2.3",
	"l1liutkqText": "-2.9",
	"l1liutkrText": "***",
	"l1liutksText": "***",
	"l1liutktText": "***",
	"l1liutkuText": "***",
	"l1liutkvText": "***",
	"l1liutkwText": "***",
	"l1liutkxText": "-6.9",
	"l1liutkyText": "***",
	"l1liutkzText": "***",
	"l1liutl0Text": "Work / school",
	"l1liutl1Text": "F<span class=\"_ _1\"></span>amily life /",
	"l1liutl2Text": "home responsibilities",
	"l1liutl3Text": "Social life<span class=\"_ _10\"></span>T<span class=\"_ _9\"></span>otal",
	"l1liutl4Text": "-8.7",
	"l1liutl5Text": "Clinically<span class=\"_ _7\"></span> meaningf<span class=\"_ _7\"></span>ul chang<span class=\"_ _7\"></span>e<span class=\"fs12 ls0 v5\">2</span>",
	"l1liutl6Text": "W<span class=\"_ _7\"></span>e<span class=\"_ _7\"></span>e<span class=\"_ _11\"></span>k<span class=\"_ _7\"></span> 12<span class=\"_ _12\"> </span><span class=\"fc9 ls5 ws10\">We<span class=\"_ _7\"></span>e<span class=\"_ _7\"></span>k<span class=\"_ _7\"></span> 24</span>",
	"l1liutl7Text": "Severely impair<span class=\"_ _1\"></span>ed patients",
	"l1liutl8Text": "Early initiation",
	"l1liutl9Text": "Improvements in a r<span class=\"_ _1\"></span>eal-world setting were also seen in depression <br>severity (as measur<span class=\"_ _1\"></span>ed by PHQ-9), cognitive function (as measured <br>by PDQ-5 and DSST) and HRQoL (as measured by EQ-5D-5L)<span class=\"fs2 v1\">¶1</span>",
	"Brintellix_NewAss_33f7933f3": "<span style=\"color:#4d7f86; font-size:20px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><div style=\"text-align: center;\">Change from baseline in SDS scores at week 12 and week 24<sup style=\"font-size: 50%;\">§</sup></div></span>",
	"Brintellix_NewAss_38f67eee5": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">Total</div>",
	"Brintellix_NewAss_3cd7ef890": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">Work / school</div>",
	"Brintellix_NewAss_3a2535f3b": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">Social life</div>",
	"Brintellix_NewAss_3ef4af64c": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">Family life /<br>home responsibilities</div>",
	"Brintellix_NewAss_3fc1f0ac9": "<div style=\"text-align: center; color:#4d7f86; font-size:15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\">LS mean change from baseline</div>",
	"Brintellix_NewAss_318daa4d1": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-6.9</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_3b6528d57": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-8.7</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_3599dc0bc": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-2.2</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_33b4710ba": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-2.9</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_3c53d6a54": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-2.4</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_3339c7cc0": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-3.0</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_3df16426f": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-2.3</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_3d417f5f7": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:12px; font-family: '9_SCCHXC+AvenirNext-Regular'; margin-bottom:15px;\">-2.9</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">***</p>\n</div>",
	"Brintellix_NewAss_342561680": "<font style=\"color:#5e6b73; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:13px;\">Clinically meaningful change<sup style=\"font-size:50%;\">2</sup></font>",
	"Brintellix_NewAss_3299bd43e": "<font style=\"color:#5e6b73; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:13px;\">Week 12</font>",
	"Brintellix_NewAss_339a303c3": "<font style=\"color:#578f99; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:13px;\">Week 24</font>",
	"Brintellix_NewAss_3bc526093": "<div style=\"color:#646162; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> Improvements in a real-world setting were also seen in depression<br>severity (as measured by PHQ-9), cognitive function (as measured<br>by PDQ-5 and DSST) and HRQoL (as measured by EQ-5D-5L)<sup style=\"font-size:50%;\">¶1</sup></div>",
	"Brintellix_NewAss_37f14f068": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">\n<sup style=\"font-size:50%;\">†</sup>Improvements of ≥4 points in total score and between 1-2 in subscale scores are considered clinically meaningful.<sup style=\"font-size:50%;\">2</sup><br>\n<sup style=\"font-size:50%;\">‡</sup>As measured by SDS.<br>\n<sup style=\"font-size:50%;\">§</sup>Analysis of data based on non-interventional, multi-national, prospective cohort study in 737 outpatients initiating treatment with<br>Brintellix<sup style=\"font-size:50%;\">®</sup> for MDD. SDS baseline scores: SDS total score = 19.6, SDS work/school score = 6.3, SDS family life/home responsibilities<br>score = 6.6, SDS social life score = 6.7.<br>\n***p&lt;0.001 vs baseline.<br>\nEQ-5D-5L, EuroQoL 5 dimension 5 level; DSST, digit symbol substitution test; HRQoL, health-related quality of life; LS, least square;<br>MDD, major depressive disorder; MDE: major depressive episode; PDQ-5, perceived deficits questionnaire – depression 5-item<br>version; PHQ-9, patient health questionnaire 9-item version; SDS, Sheehan disability scale.\n</div>",
	"Brintellix_NewAss_30a4a9538": "<span style=\"color: rgb(77, 127, 134); font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_NewAss_3216c4b14": "<font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font><div style=\"margin:5px 0 0;\"><font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>2.</b></font></div>",
	"Brintellix_NewAss_36ab181b0": "<div style=\"margin-bottom:5px;\"><font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Mattingly G et al. Poster presented at ECNP. P.0724. 2021.</font></div>\n<div><font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Sheehan KH, Sheehan DV. Int Clin Psychopharmacol 2008;23:70-83.</font></div>",
	"Brintellix_NewAss_3d746b63a": "<font style=\"font-size: 17px; font-family: '3_SCCHXC+Avenir-Black'; color: #FFF;\">Severely impaired patients</font>",
	"Brintellix_NewAss_3ecfbd9d9": "<font style=\"font-size: 17px; font-family: '3_SCCHXC+Avenir-Black'; color: #FFF;\">Early initiation</font>",
	"Brintellix_NewAss_3d7c21a5e": "<font style=\"font-size: 26px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';color: rgb(77, 127, 134); line-height:1.2;\">The proportion of patients whose functioning<sup style=\"font-size:50%;\">†</sup> was severely<br>impaired decreased from 52% to 15%, after 24 weeks of treatment<br>with Brintellix<sup style=\"font-size:50%;\">®‡1</sup></font>",
	"Brintellix_NewAss_37a7ee106": "<div style=\"text-align:center; font-size: 20px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';color: #4d7f86;\">Change in overall functioning (SDS total score categories<sup style=\"font-size:50%;\">§</sup>)<br>over 24 weeks in routine clinical practice</div>",
	"Brintellix_NewAss_3fe45482b": "<div style=\"text-align:center; font-size: 15px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';color: #4d7f86;\">Patients in SDS category (%)</div>",
	"Brintellix_NewAss_3da8d08a7": "<div style=\"text-align:center; font-size: 12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';color: #4d7f86;\">Minimally<br>affected</div>",
	"Brintellix_NewAss_3b134d40b": "<div style=\"text-align:center; font-size: 12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';color: #4d7f86;\">Mildly<br>affected</div>",
	"Brintellix_NewAss_31042ecfb": "<div style=\"text-align:center; font-size: 12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';color: #4d7f86;\">Moderately<br>affected</div>",
	"Brintellix_NewAss_3d553cb25": "<div style=\"text-align:center; font-size: 12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';color: #4d7f86;\">Severely<br>affected</div>",
	"Brintellix_NewAss_30f5a8018": "<div style=\"color:#569099; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:13px; margin-bottom:19px;\">Baseline</div>\n<div style=\"color:#e88200; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:13px; margin-bottom:19px;\">Week 12</div>\n<div style=\"color:#5f6a72; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:13px;\">Week 24</div>",
	"Brintellix_NewAss_3a14ea204": "<div style=\"color:#646162; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px; margin-bottom:50px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> In routine clinical practice, almost <b style=\"font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\">3 in 4 patients</b> with MDD (74%) present with co-morbidities<sup style=\"font-size:50%;\">¶1</sup></div>",
	"Brintellix_NewAss_349d7acef": "<div style=\"text-align: center; color:#4d7f86; font-size:13px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\">Level of functional impairment</div>",
	"Brintellix_NewAss_3c378f9cc": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">\n<sup style=\"font-size:50%;\">†</sup>As measured by SDS.<br>\n<sup style=\"font-size:50%;\">‡</sup>Analysis of data based on non-interventional, multi-national, prospective cohort study in 737 outpatients initiating treatment with Brintellix<sup style=\"font-size:50%;\">®</sup> for MDD. Inclusion criteria aged ≥18 years and current MDE.<br>\n<sup style=\"font-size:50%;\">§</sup>Scores of 0-5, 6-11, 12-20 and 21-30 represent cut-off ranges of minimally, mildly, moderately, and markedly affected categories, respectively.<sup style=\"font-size:50%;\">1,2</sup><br>\n<sup style=\"font-size:50%;\">¶</sup>Patients presented various comorbidities at study initiation, including sleep disorders (22%), cardiovascular disease (16.7%), chronic pain (8.5%), diabetes<br>(7.2%), chronic fatigue (6.1%), neurological disorder (6.0%), smoking (4.7%). SDS baseline scores: SDS total score = 19.6.<br>\nSDS, Sheehan disability scale.<br><br>\n<b style=\"font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\">1.</b> Mattingly G et al. Poster presented at ECNP. P.0724. 2021.<br>\n<b style=\"font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\">2.</b> Sheehan KH, Sheehan DV. Int Clin Psychopharmacol 2008;23:70-83.\n</div>",
	"Brintellix_NewAss_3c39e011c": "<font style=\"font-size: 23px; font-family: '2_TKMNLA+AvenirNextLTPro-Bold';color: rgb(77, 127, 134); line-height:1.2;\">Patients with MDD treated with Brintellix<sup style=\"font-size:50%;\">®</sup> demonstrated improvements<br>in functioning, depression severity, cognition and quality of life<sup style=\"font-size:50%;\">†1</sup></font>",
	"Brintellix_NewAss_375727806": "<div style=\"text-align: center; color:#4d7f86; font-size:20px; font-family: '3_SCCHXC+Avenir-Black'; line-height:1.2\">Change from baseline to week 24 in functioning, depression severity, cognitive<br>symptoms and performance, and health-related quality of life in routine clinical practice</div>",
	"Brintellix_NewAss_305e56e6b": "<div style=\"text-align: center; color:#4d7f86; font-size:12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; margin-bottom:10px;\">Functioning</div>\n<div style=\"text-align: center; color:#5f6a72; font-size:8px; font-family: '9_SCCHXC+AvenirNext-Regular';\">SDS total</div>",
	"Brintellix_NewAss_39fe2c305": "<div style=\"text-align: center; color:#4d7f86; font-size:12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; margin-bottom:10px;\">Depression severity</div>\n<div style=\"text-align: center; color:#5f6a72; font-size:8px; font-family: '9_SCCHXC+AvenirNext-Regular';\">PHQ-9</div>",
	"Brintellix_NewAss_30d63b4be": "<div style=\"text-align: center; color:#4d7f86; font-size:12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; margin-bottom:10px;\">Cognitive symptoms</div>\n<div style=\"text-align: center; color:#5f6a72; font-size:8px; font-family: '9_SCCHXC+AvenirNext-Regular';\">PDQ-5</div>",
	"Brintellix_NewAss_3c0131f0c": "<div style=\"text-align: center; color:#4d7f86; font-size:12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; margin-bottom:10px;\">Cognitive performance</div>\n<div style=\"text-align: center; color:#5f6a72; font-size:8px; font-family: '9_SCCHXC+AvenirNext-Regular';\">DSST</div>",
	"Brintellix_NewAss_372dbf799": "<div style=\"text-align: center; color:#4d7f86; font-size:12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; margin-bottom:10px;\">HRQoL</div>\n<div style=\"text-align: center; color:#5f6a72; font-size:8px; font-family: '9_SCCHXC+AvenirNext-Regular';\">EQ-5D-5L</div>",
	"Brintellix_NewAss_3df24edea": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-10.3</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_3e07c2203": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-7.1</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_3a9f4f808": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-7.7</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_34884b023": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-8.4</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_36c77abe1": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-6.8</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_30081392a": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-6.1</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_3b72783e9": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-5.2</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_3d00a4c50": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-4.3</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_30f4d46dd": "<div style=\"text-align: center;\">\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-bottom:15px;\">-3.7</p>\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n</div>",
	"Brintellix_NewAss_355141a39": "<div style=\"text-align: center;\">\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-top:15px;\">6.8</p>\n</div>",
	"Brintellix_NewAss_341a39ff8": "<div style=\"text-align: center;\">\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-top:15px;\">5.4</p>\n</div>",
	"Brintellix_NewAss_36f85abde": "<div style=\"text-align: center;\">\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-top:15px;\">6.5</p>\n</div>",
	"Brintellix_NewAss_3c711b5e3": "<div style=\"text-align: center;\">\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-top:15px;\">0.15</p>\n</div>",
	"Brintellix_NewAss_3cd7416f7": "<div style=\"text-align: center;\">\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-top:15px;\">0.11</p>\n</div>",
	"Brintellix_NewAss_308561642": "<div style=\"text-align: center;\">\n<p style=\"color:#5f6a72; font-size:12px; font-family: 'b_SCCHXC+AvenirNext-DemiBold'\">*</p>\n<p style=\"color:#FFF; font-size:10px; font-family: 'a_SCCHXC+AvenirNext-Medium'; margin-top:15px;\">0.10</p>\n</div>",
	"Brintellix_NewAss_36f73f223": "<font style=\"color:#5f6a72; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">First treatment for current MDE (n=321)</font>",
	"Brintellix_NewAss_3c980602c": "<font style=\"color:#e88200; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">Second treatment for current MDE (n=257)</font>",
	"Brintellix_NewAss_30f0c57ce": "<font style=\"color:#569099; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; font-size:12px;\">Third or later treatment for current MDE (n=159)</font>",
	"Brintellix_NewAss_37e3163ff": "<div style=\"color:#646162; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px; margin-bottom:50px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> Patients may benefit from early initiation of Brintellix<sup style=\"font-size:50%;\">®</sup>, as shown across various measures,<br>compared to its use as a second or third treatment in a current MDE<sup style=\"font-size:50%;\">1</sup></div>",
	"Brintellix_NewAss_32c10c9fd": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">\n*p&lt;0.001 vs baseline.<br>\n<sup style=\"font-size:50%;\">†</sup>Analysis of data based on non-interventional, multi-national, prospective cohort study in 737 outpatients initiating treatment with Brintellix<sup style=\"font-size:50%;\">®</sup> for MDD. SDS<br>baseline scores: SDS total score = 19.6, SDS work/school score = 6.3, SDS family life/home responsibilities score = 6.6, SDS social life score = 6.7.<br> \nDSST, digit symbol substitution test; EQ-5D-5L, EuroQoL 5-dimension, 5-level; HRQoL, health-related quality of life; MDD, major depressive disorder; MDE, major<br>depressive episode; PDQ-D-5, perceived deficits questionnaire – depression 5-item version; PHQ-9, patient health questionnaire 9-item version; SDS, Sheehan<br>disability scale.<br><br>\n<b style=\"font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\">1.</b> Mattingly G et al. Poster presented at ECNP. P.0724. 2021.\n</div>",
	"Brintellix_NewAss_3704c9043": "Text",
	"Brintellix_NewAss_39348c170": "Text"
}
